News | Optical Coherence Tomography (OCT) | August 05, 2021

FDA Clears Abbott OCT Imaging Enhanced With Artificial Intelligence

Ultreon 1.0 Software merges optical coherence tomography with the power of automation using artificial intelligence

Abbott's new interventional imaging platform powered by Ultreon 1.0 Software is a first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

Abbott's new interventional imaging platform powered by Ultreon 1.0 Software is a first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

August 5, 2021 — The U.S. Food and Drug Administration (FDA) has cleared clearance Abbott's latest optical coherence tomography (OCT) imaging platform powered by the company's new Ultreon Software. It combines OCT with artificial intelligence (AI) to provide physicians an enhanced, comprehensive view of coronary blood flow and blockages to assist physician decision-making in the cath lab and provide the best pathway for treatment.

U.S. clearance follows the recently attained CE mark in Europe, providing broader access to the latest OCT imaging platform for interventional cardiologists seeking to utilize the latest in AI-powered technology. Ultreon Software integrates with Abbott's new Dragonfly OpStar imaging catheter and PressureWire X guidewire to provide physicians access to a broad set of tools to assess coronary blood flow and blockages and improve treatment planning for patients.   

"Abbott's new Ultreon Software for OCT provides an automated, comprehensive view of the artery that facilitates physician decision-making," said Ziad Ali, M.D., D.Phil, director of the DeMatteis Cardiovascular Institute at St. Francis Hospital and Heart Center in New York. "Ultreon Software guides stents to be placed with precision. These types of innovative technologies are instrumental in providing the best care for our patients."

Earlier this year, an annual study by Abbott titled Beyond Intervention revealed that physicians view forward-thinking and innovative technologies as critical components to providing the best patient care. According to the research, 83.2% of physicians agreed that advances in diagnostic and treatment technologies, such as OCT, have translated to tangible improvements in patient care.

"As cardiologists continue to adopt OCT and move away from traditional imaging methods such as angiography, emerging technologies are pivotal to determine the best course of patient care," said Nick West, M.D., chief medical officer and divisional vice president of global medical affairs at Abbott's vascular business. "AI enables Ultreon Software to automatically detect calcium and vessel diameters allowing doctors to put stents exactly where they are needed."

The launch of Ultreon Software for OCT in the United States demonstrates Abbott's commitment to continual innovation in the global vascular community with the latest medical devices and technologies. For example, recent data shows that when OCT is paired with Abbott's MLD MAX, a new workflow that helps guide and optimize stenting decisions, physicians have altered their treatment strategy in treating 88% of coronary artery blockages.[1] Abbott's latest technologies play a vital role in improving cardiovascular patient care and achieving optimal outcomes during and after intervention. 

For U.S. important safety information on Ultreon, visit: https://abbo.tt/3qAujzc

Abbott showcased Ultreon Software for the first time at EuroPCR 2021 and recently received approval in Japan.

For more information: www.abbott.com

Reference:

1. https://abbott.mediaroom.com/2020-06-26-New-Research-Finds-Abbotts-Optical-Coherence-Tomography-Imaging-Changed-Treatment-Decisions-in-88-of-Artery-Blockages 

Related Content

An example of artificial intelligence on the GE Healthcare Vivid E95 system shown at ASE 2019 where the AI automatically pulls in an exam, identifies the left ventricle and myocardial boards and then calculates all the strain measurements in less than 10 seconds. While AI automation can greatly speed workflow, there are questions about the accuracy of AI for the next step in making diagnoses.  #ASE #ASE21 #ASE2021 #AI

An example of artificial intelligence on the GE Healthcare Vivid E95 system shown at ASE 2019 where the AI automatically pulls in an exam, identifies the left ventricle and myocardial boards and then calculates all the strain measurements in less than 10 seconds. While AI automation can greatly speed workflow, there are questions about the accuracy of AI for the next step in making diagnoses. 

Feature | Artificial Intelligence | September 08, 2021 | By Dave Fornell, Editor
Artificial intelligence is becoming best practice to support clinical decisions and help standardize echocardiography analysis for practices. AI, trained on millions of outcome-based data, can provide automation for operators to obtain highly accurate and precise measurements, to better detect and predict cardiovascular disease.
Webinar | Artificial Intelligence | August 12, 2021
Artificial intelligence is becoming best practice to support clinical decisions and help standardize echocardiography
An example of Viz.AI's pulmonary embolism AI application and mobile alert to the physician on-call. Viz.AI and Avicenna.AI Partner to Launch Artificial Intelligence Care Coordination for Pulmonary Embolism and Aortic Disease

An example of Viz.AI's pulmonary embolism AI application and mobile alert to the physician on-call.

News | Artificial Intelligence | July 21, 2021
July 21, 2021 — Artificial int...
Circle Cardiovascular Imaging Partners With DiA Imaging Analysis to Deliver AI-Based Cardiovascular Imaging Solutions
News | Artificial Intelligence | June 28, 2021
June 28, 2021 — Circle Cardiovascular Imaging Inc. and DiA Imaging Analysis Ltd.
Point of care ultrasound, POCUS, combined with artificial intelligence, can help improve echo image quality by inexperienced sonographers.

Getty Images

News | Artificial Intelligence | June 25, 2021
June 25, 2021 – COVID-19 changed everything in healthcare, and a benefit from this pandemic was a surge in innovation
GE is integrating artificial intelligence into most of its imaging and information technology software. AI can aid fast critical care decision making. Above left is the vScan Air wireless point-of-care ultrasound system. It integrates AI for immediate, automated assessment of a patient's ejection fraction, right.

GE is integrating artificial intelligence into most of its imaging and information technology software. AI can aid fast critical care decision making. Above left is the vScan Air wireless point-of-care ultrasound system. It integrates AI for immediate, automated assessment of a patient's ejection fraction, right.

Feature | Artificial Intelligence | June 10, 2021
The digital transformation of healthcare is underway, but it will advance further and faster if key stakeholders work
AI Med will present its Virtual Clinical Series: Imaging Built by Clinicians, for Clinicians, June 29-30, 2021.
News | Artificial Intelligence | June 09, 2021
June 9, 2021 — AI Med will present its...